Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Location status: Recruiting
NCT Number: NCT07083011
The purpose of this study is to assess the performance of 68Ga- FAPI PET in heart failure with preserved ejection fraction (HFpEF)
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Phase 2
Rochester, Minnesota, 55905, United States
Location status: Recruiting
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
HFpEF Group Inclusion:
HFpEF Group Exclusion:
Cardiac Sarcoid Group Inclusion:
Cardiac Sarcoid Group Exclusion:
Healthy Controls Group Inclusion:
Healthy Controls Group Exclusion:
68Ga-FAPI is a gallium-68 fibroblast activation protein inhibitor that will be injected into subjects during a PET (positron emission tomography) scan
Time frame: Baseline and 6 Months
Myocardial 68Ga-FAPI volume will be determined by a PET (positron emission tomography) scan and measured in cm3
Time frame: Baseline and 6 Months
SUVmean and SUVmax will be determined by a PET (positron emission tomography) scan and measured as a dimensionless ratio
Time frame: Baseline and 6 Months
Area of 68Ga-FAPI will be determined by a PET (positron emission tomography) scan and measured as a % of polar map.
Time frame: Baseline and 6 Months
68Ga-FAPI target-to-background ratio will be determined by a PET (positron emission tomography) scan and measured as a dimensionless ratio.
Contact information is provided by the study sponsor or research team.
Mayo Clinic
Other
A Three-Arm, Observational, Pilot Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06081543
Cardiovascular Diseases, Heart Diseases
Columbus, Ohio, United States
View Trial DetailsNCT07202000
Heart Failure With Preserved Ejection Fraction
Boston, Massachusetts, United States
View Trial DetailsNCT07214376
Cardiovascular Diseases, Heart Diseases
Houma, Louisiana, United States
View Trial DetailsNCT05525663
Heart Failure With Preserved Ejection Fraction
Winston-Salem, North Carolina, United States
View Trial Details